The Bulletin
The Times


.

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

  • Written by PR Newswire

NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its Investigational New Drug (IND)...

The Bulletin Magazine

Executive Recruitment for Education Leadership: What Schools Should Consider

Practical Guide to Roller Shutters for Safer, More Comfortable Homes

Why the Advertised Rate on a Bonus Saver Account Isn't What Most Savers Actually Earn

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

Cryotherapy in Melbourne: What Skin Lesions Can Be Treated with Targeted Cold Therapy?

hacklink casinos not on gamstopcasinos non gamblock ukiptviptvzlibraryzlibraryz-librarybursa escortMeritbetdeneme bonusuPadişahbetvippark kayıtPadişahbetdeneme bonusulunabet girişPadişahbettaraftarium24Sahabetjojobetjojobetjojobetviljo kasinot kirjautuminenGalabetzimpler kasinotGalabet1xbetjojobetcasibomcasibomjojobettaraftarium24holiganbet